

# Alma D Campos-Parra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8019123/publications.pdf>

Version: 2024-02-01

26  
papers

1,134  
citations

430874

18  
h-index

552781

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2085  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers. <i>Current Oncology</i> , 2022, 29, 4689-4702.	2.2	10
2	Negative Regulation of Serine Threonine Kinase 11 (STK11) through miR-100 in Head and Neck Cancer. <i>Genes</i> , 2020, 11, 1058.	2.4	10
3	Identification of miRNA Master Regulators in Breast Cancer. <i>Cells</i> , 2020, 9, 1610.	4.1	20
4	miRNA profile obtained by next-generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments. <i>International Journal of Molecular Medicine</i> , 2019, 44, 1267-1280.	4.0	16
5	Crosstalk Between Long Non-coding RNAs, Micro-RNAs and mRNAs: Deciphering Molecular Mechanisms of Master Regulators in Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 669.	2.8	184
6	A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population. <i>Cancers</i> , 2019, 11, 1246.	3.7	9
7	HypoxamiRs Profiling Identify miR-765 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 381.	2.8	25
8	Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN-AKT axis. <i>Cancer Cell International</i> , 2019, 19, 80.	4.1	38
9	BRCA mutations: is everything said?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 49-54.	2.5	12
10	MicroRNA-125 modulates radioresistance through targeting p21 in cervical cancer. <i>Oncology Reports</i> , 2018, 39, 1532-1540.	2.6	23
11	Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2711.	4.1	43
12	A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770289.	1.8	29
13	Alternative splicing regulation in tumor necrosis factor-mediated inflammation (Review). <i>Oncology Letters</i> , 2017, 14, 5114-5120.	1.8	10
14	Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1182.	4.1	39
15	Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer. <i>Journal of Cancer</i> , 2016, 7, 1632-1644.	2.5	18
16	MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review). <i>Oncology Reports</i> , 2016, 35, 3-12.	2.6	50
17	Comprehensive transcriptome analysis identifies pathways with therapeutic potential in locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2016, 143, 406-413.	1.4	22
18	The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 169-175.	2.0	81

#	ARTICLE	IF	CITATIONS
19	Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). <i>Journal of Thoracic Oncology</i> , 2015, 10, 838-843.	1.1	156
20	KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 33-40.	1.3	39
21	Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. <i>European Respiratory Journal</i> , 2014, 43, 1439-1447.	6.7	55
22	Clinical and Pathological Characteristics, Outcome and Mutational Profiles Regarding Non-Small-Cell Lung Cancer Related to Wood-Smoke Exposure. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1228-1234.	1.1	48
23	Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1955-1959.	1.1	113
24	Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. <i>Neurology</i> , 2011, 77, 987-995.	1.1	61
25	EhNCABP166: A nucleocytoplasmic actin-binding protein from <i>Entamoeba histolytica</i> . <i>Molecular and Biochemical Parasitology</i> , 2010, 172, 19-30.	1.1	20
26	<i>Entamoeba histolytica</i> EhGEF1 structure and mutational analysis: New specific residues critical for function. <i>Molecular and Biochemical Parasitology</i> , 2009, 164, 118-125.	1.1	3